PharmTech News

Feliza Mirasol is the science editor for 

Articles

EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.

Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert

With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.

Lonza to Provide Tailored Offering for the Development of Oral Biologics Using Smart Capsules

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies. 

Behind the Headlines: Pandemic Preparedness, Novel mRNA Applications, and More

A new platform allowing market authorization holders to report drug shortages has gone live. 

EMA Announces Drug Monitoring Platform

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Aligned with our audience’s preferences, PTE will be a fully digital publication from 2025 onwards.

New Year, New PTE

The acquisition will provide Roche with access to Poseida’s GMP manufacturing capabilities and R&D portfolio assets, including cell therapy candidates.

Roche Enters Definitive Merger Agreement to Acquire Poseida Therapeutics

Through this acquisition, the German CDMO expands its global network and adds aseptic fill/finish and lyophilization expertise to its sterile manufacturing capabilities.

Adragos Pharma Strengthens Sterile Manufacturing Capabilities with Baccinex Acquisition

Nicholas Saraceno is editor at Pharmaceutical Commerce.

FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.

FDA Grants Approval to Kedrion to Produce PLGD-1 Therapeutic at Bolognana Plant

The company has expanded its early and late phase analytical capabilities by including GMP cell-based potency assays at its sites in Cambridge, UK, and San Diego, Calif.

Abzena Expands Analytical Services with GMP Cell-Based Potency Testing in US and UK

Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France. 

PharmTech Europe News